Madrigal Pharmaceuticals(MDGL) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - Fourth quarter 2025 net sales reached $321.1 million, more than tripling from fourth quarter 2024 [5][23] - Full year 2025 net sales totaled $958.4 million, marking an exceptional launch by industry standards [5][23] - The gross to net impact increased from the third quarter to the fourth quarter, with a full year average at the low end of the 20%-30% range [23][24] Business Line Data and Key Metrics Changes - Rezdiffra established itself as the foundational therapy in MASH, with nearly $1 billion in net sales for its first full year [3][5] - The number of patients on Rezdiffra increased to over 36,250 by the end of the fourth quarter, up from more than 29,500 at the end of the third quarter [8][23] Market Data and Key Metrics Changes - The U.S. MASH market has grown nearly 50% since the end of 2023 and is expected to continue growing at a double-digit pace [3][9] - The target population of 315,000 representative patients seen by target specialists has expanded significantly, indicating a growing market [9] Company Strategy and Development Direction - The company aims to build a sustainable franchise around Rezdiffra, with a pipeline designed to extend leadership in the MASH category [4][5] - The strategy includes advancing combination therapies and leveraging a high-quality pipeline to address distinct patient subpopulations [12][17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in robust net sales growth for 2026, despite anticipated increases in gross to net from contracting [24][40] - The company is well-positioned to lead in MASH, with expectations for continued patient additions and market expansion [27][63] Other Important Information - R&D expenses for 2025 were $388.5 million, primarily due to business development activities [25] - The company ended the fourth quarter with $988.6 million in cash and equivalents, providing strong resources for ongoing initiatives [26] Q&A Session Summary Question: What are the drivers of growth in diagnosed patients and expectations for category growth in 2026? - Management noted strong growth driven by increased awareness and the presence of competitors like Novo, leading to more diagnoses and a clearer path to peak [31][33] Question: What is the contribution of the Germany launch to worldwide revenues and patient numbers? - The contribution from Germany was negligible in 2025, with limited expectations for 2026 as the U.S. remains the primary market [39][40] Question: How is the company tracking blinded event rates for MAESTRO-NASH outcomes? - Management indicated that event rates are tracking as expected, with data delivery anticipated in 2027 [50] Question: What is the expected gross to net for Q1 and the rest of 2026? - The gross to net discount is expected to be in the high thirties for 2026, with broad first-line access and no step edits [57][59] Question: How important is maintaining adherence rates for revenue growth? - Management emphasized the importance of adherence, with ongoing initiatives to improve persistence rates among patients [62][66]